Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 1/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | NPY4R | P50391 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 3/20 | 0.51 |
| ▸ | MME | P08473 | 3/20 | 0.51 |
| ▸ | ACE | P12821 | 3/20 | 0.51 |
| ▸ | CPA1 | P15085 | 2/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17948645 | 0.94 | LTA4H (0.58) | NPY1RNPY2RNPY4RLTA4HBACE1 | |
| Hydrochloric Acid SCHEMBL19741503 | 0.92 | LTA4H (0.57) | NPY1RNPY2RNPY4RLTA4HBACE1 | |
| Hydrochloric Acid SCHEMBL19741504 | 0.92 | LTA4H (0.57) | NPY1RNPY2RNPY4RLTA4HBACE1 | |
| SCHEMBL22503664 | 0.91 | ACE (0.59) | MMEACECPA1ACE2 | |
| SCHEMBL8267315 | 0.89 | CTSL (0.52) | NPY1RNPY2RNPY4RLTA4HBACE1 | |
| SCHEMBL2628283 | 0.86 | ANPEP (0.56) | MMP3LTA4HBACE1MME | |
| SCHEMBL15581384 | 0.86 | ERAP2 (0.55) | MMP3LTA4HMMECPA1 | |
| SCHEMBL17706116 | 0.85 | LTA4H (0.61) | MMP3LTA4HMME | |
| SCHEMBL29775566 | 0.85 | LTA4H (0.58) | NPY1RNPY2RNPY4RLTA4HBACE1 | |
| SCHEMBL8269340 | 0.84 | MME (0.55) | NPY1RNPY2RNPY4RLTA4HMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | MMP3 534/4885NPY1R 2267/4885NPY2R 2732/4885 |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | MMP3 407/4885NPY1R 2925/4885NPY2R 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.